Company intelligence
BioIVT
ELEVATING SCIENCE
About BioIVT
BioIVT, formerly BioreclamationIVT, is a leading global provider of high-quality biological specimens and value-added services. We specialize in control and disease state samples including human and animal tissues, cell products, blood and other biofluids. Our unmatched portfolio of clinical specimens directly supports precision medicine research and the effort to improve patient outcomes by coupling comprehensive clinical data with donor samples. Our Research Services team works collaboratively with clients to provide in vitro hepatic modeling solutions. And as the world’s premier supplier of ADME-Tox model systems, including hepatocytes and subcellular fractions, BioIVT enables scientists to better understand the pharmacokinetics and drug metabolism of newly discovered compounds and the effects on disease processes. By combining our technical expertise, exceptional customer service, and unparalleled access to biological specimens, BioIVT serves the research community as a trusted partner in ELEVATING SCIENCE®.
Verified activity
Signals from BioIVT
9 published signals
Research & Knowledge
BioIVT published results from a new publication featuring researchers using the HEPATOPAC long-term hepatic MPS micropatterned co-culture system.
Reported by Jackie Bowlin
Research & Knowledge
BioIVT learned about the EMA's new Voluntary Data Submission program, which will provide participants with individual, non-binding, and non-decisional feedback on the regulatory relevance and readiness of their NAM or weight-of-evidence approach.
Reported by Michael Millhollen
Presence & Recognition
BioIVT employee Courtney Noah presented a multi-omics biomarker discovery watch on oncology therapies and biomarker strategies.
Reported by Cathie G. Miller, PhD
Research & Knowledge
BioIVT published results from a new publication featuring researchers using the HEPATOPAC long-term hepatic MPS micropatterned co-culture system.
Reported by Charlie Chungu
Research & Knowledge
BioIVT presented an innovative approach for the preclinical evaluation of the BA-induced hepatotoxic potential of drug candidates in the EUROTOX2026 e-poster LP-71.
Reported by Cathie G. Miller, PhD
Research & Knowledge
BioIVT published data showing the quality of its leukopaks in comparison with competitors via Akadeum.
Reported by Cathie G. Miller, PhD
Research & Knowledge
BioIVT published results from a new publication featuring researchers using the HEPATOPAC long-term hepatic MPS micropatterned co-culture system.
Reported by Cathie G. Miller, PhD
Presence & Recognition
BioIVT received an update from the American Association of Pharmaceutical Scientists (AAPS) regarding the registrations for the NAMs event.
Reported by Michael Millhollen
Presence & Recognition
BioIVT announced that Dr. Brian Ogilvie will be presenting a presentation on donor-stratified adipocyte, hepatocyte, and biospecimen models to investigate metabolic heterogeneity, hepatic metabolism, inflammation, and toxicity.
Reported by Michael Millhollen